I-Mab Biopharma US Limited

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, I-Mab Biopharma US Limited sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 2 currently recruiting 5 completed early-phase tilt upper quartile by trial count

I-Mab Biopharma US Limited: 7 sponsored US clinical trials, 2 recruiting.

I-Mab Biopharma US Limited sponsors 7 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gastroesophageal Junction Carcinoma, with 2 trials.

Upper-quartile sponsor footprint

I-Mab Biopharma US Limited sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

7 total, page 1 of 1

RECRUITING Phase 2

Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)

NCT07432295
RECRUITING Phase 1

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

NCT04900818
COMPLETED Phase 2

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

NCT05001347
COMPLETED Phase 1

Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors

NCT04678921
COMPLETED Phase 2

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

NCT04341116
COMPLETED Phase 1

Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

NCT03934814
COMPLETED Phase 1

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Healthy Adult Subjects

NCT03794180

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 3

Therapeutic Areas

Gastroesophageal Junction Carcinoma 2
Gastric Cancer 2
Advanced Cancer 2
Metastatic Cancer 2
Esophageal Adenocarcinoma 2
Solid Tumor 2
Biliary Tract Cancer (BTC) 1
PDAC - Pancreatic Ductal Adenocarcinoma 1

What is open in the I-Mab Biopharma US Limited pipeline

2 recruiting of 7 indexed (29% open); 5 completed (71%).

Phase mix: 0 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Gastroesophageal Junction Carcinoma (2 trials), 7 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

I-Mab Biopharma US Limited: open-pipeline peers nationwide

Peers matched on 7 registered trials and 29% open enrollment, not the therapeutic-area sidebar.

I-Mab Biopharma US Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30%40% Total trials Recruiting share I-Mab Biopharma US Limited3M4Life Research89bioAbbott Diagnostics DivisionAlabama Physical Therapy & AcupunctureAlloSourceAlnylam PharmaceuticalsAnnovis Bio
I-Mab Biopharma US Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

I-Mab Biopharma US Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 29% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this I-Mab Biopharma US Limited page

7 registered trials is a research-attention snapshot, not an endorsement of I-Mab Biopharma US Limited or any single study.

  • 2 of I-Mab Biopharma US Limited's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Gastroesophageal Junction Carcinoma is the condition I-Mab Biopharma US Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gastroesophageal Junction Carcinoma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

I-Mab Biopharma US Limited pipeline card: 7 registered trials from official public datasets.Report a data error.